Novartis Scraps Sale of Sandoz Assets to Aurobindo
April 02 2020 - 1:47AM
Dow Jones News
By Kim Richters
Novartis AG said Thursday that it has canceled the divestment of
the U.S. generic oral solids and dermatology businesses of its
subsidiary Sandoz to Aurobindo Pharma USA Inc.
The Swiss drug maker said the decision was taken mutually after
they didn't receive approval for the deal from the U.S. Federal
Trade Commission "within anticipated timelines."
The Sandoz assets will continue to operate as part of Sandoz's
U.S. business, Novartis said.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
April 02, 2020 01:32 ET (05:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Sep 2023 to Sep 2024
